Kodiak Sciences Inc (KOD)
$3.38
+0.05
(+1.5%)▲
Insights on Kodiak Sciences Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 49.7% return, outperforming this stock by 76.2%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 337.9%
Performance
- $3.26$3.45$3.38
3.55%
Downside
Day's Volatility :5.51%
Upside
2.03%
- $1.37$9.80$3.38
59.47%
Downside
52 Weeks Volatility :86.02%
Upside
65.51%
Returns
| Period | Kodiak Sciences Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -29.73% | 1.7% | 0.0% |
6 Months | 141.43% | 11.3% | 0.0% |
1 Year | -26.52% | 5.4% | 1.3% |
3 Years | -97.33% | 13.9% | -22.1% |
Highlights
Market Capitalization | 174.9M |
Book Value | $5.08 |
Earnings Per Share (EPS) | -4.97 |
Wall Street Target Price | 4.25 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -30.25% |
Return On Equity TTM | -74.22% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -259.0M |
Diluted Eps TTM | -4.97 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -4.44 |
EPS Estimate Next Year | -4.44 |
EPS Estimate Current Quarter | -0.77 |
EPS Estimate Next Quarter | -0.89 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 25.74%
Technicals Summary
Sell
Neutral
Buy
Kodiak Sciences Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Kodiak Sciences Inc | -44.77% | 141.43% | -26.52% | -97.33% | -54.01% |
 Moderna, Inc. | -1.39% | 41.81% | -19.31% | -38.71% | 322.88% |
 Regeneron Pharmaceuticals, Inc. | -5.68% | 13.74% | 14.81% | 80.88% | 159.02% |
 Novo Nordisk A/s | -2.24% | 29.49% | 49.67% | 240.51% | 421.0% |
 Vertex Pharmaceuticals Incorporated | -3.67% | 10.39% | 20.74% | 84.71% | 129.52% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Kodiak Sciences Inc | NA | NA | NA | -4.44 | -0.74 | -0.3 | NA | 5.08 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.77 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.13 | 26.13 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 48.36 | 48.36 | 2.4 | 3.34 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 29.17 | 29.17 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Kodiak Sciences Inc | Sell | $174.9M | -54.01% | NA | 0.0% |
Moderna, Inc. | Buy | $41.3B | 322.88% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.6B | 159.02% | 26.13 | 30.14% |
Novo Nordisk A/s | Buy | $573.9B | 421.0% | 48.36 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $104.7B | 129.52% | 29.17 | 36.68% |
Institutional Holdings
Baker Bros Advisors LP
32.97%BlackRock Inc
7.68%Acadian Asset Management LLC
3.63%Newtyn Management LLC
3.37%Vanguard Group Inc
3.13%ICONIQ Capital, LLC
1.94%
Corporate Announcements
Kodiak Sciences Inc Earnings
Kodiak Sciences Inc’s price-to-earnings ratio stands at None
Read More
Company Information
about kodiak kodiak is a high-science retinal medicines development company. we are aspiring to build a dominant global retina franchise. we are developing a top pipeline of proprietary best-in-class medicines for the treatment of patients with age-related macular degeneration and diabetic eye disease, two leading causes of blindness. our science begins with an antibody biopolymer product platform merging the fields of biologics and chemistry based therapies. in our medicines we aim to restore vision, to stop progression of underlying disease, and to require fewer treatments. working at kodiak we are passionate about preventing blindness and improving health. we take pride in scientific and operational excellence. the curiosity, creativity, and courage of our team members drives our progress. we highly value this culture and support it every way we can. kodiak supports a vibrant and active lifestyle. we have a top benefits package. we are within walking distance to california avenue sh
Organization | Kodiak Sciences Inc |
Employees | 111 |
CEO | Dr. Victor Perlroth M.D. |
Industry | Health Technology |
